Patient P-01819
Synthetic patientNBL-101 · Day 119 · 45–54 · F · baseline S13Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
19%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S13
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Toxicity+15
- Inflammatory activity+8
- GI instability-4
- Treatment adherence+3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion16.6/100
stable · +0.1 vs previous 14 d
Toxicity
Blood36/100
improving · -5.5 vs previous 14 d
Sleep quality
Wearable38.6/100
stable · +0.3 vs previous 14 d
Energy level
Daily log5.7/10
improving · +0.3 vs previous 14 d
Stress level
Daily log5.9/10
stable · -0.2 vs previous 14 d
Steps
Wearable4,511
improving · +194 vs previous 14 d
Adherence
Companion90.4 %
improving · +7.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 77 from the failing basin, 15 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- HY-01 Hydration Protocolonly 33% improved among 9 similar
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Simple carbohydrates+2.1no signal · 36%
- Alcohol+1.4no signal · 29%
- Spicy / capsaicin+1.4no signal · 23%
- Histamine load+1.2no signal · 26%
- Dietary fat load+0.5no signal · 15%
- Insoluble fibre-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓45
- WearableResting HR 75 bpm
- WearableShort sleep window
- Inflammatory signalling ↑35
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 26 ms, trending down
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.6 · butyrate capacity 81/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 31 ms
- Sleep
- 6.4 h
- Steps
- 3,712
- Resting HR
- 75 bpm
Daily log: GI score 17, nutritional resilience 62, adherence 90.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 43% | S19 | AD-05 | improved | 61 |
| P-01766 | 28% | S05 | AD-05 | no change | 90 |
| P-01541 | 27% | S09 | AD-05 | no change | 43 |
| P-01377 | 26% | S11 | AD-05 | no change | 42 |
| P-01329 | 30% | S08 | BR-03 | improved | 79 |
| P-01495 | 29% | S07 | BR-03 | improved | 85 |
| P-01677 | 27% | S05 | BR-03 | no change | 86 |
| P-01689 | 27% | S13 | BR-03 | no change | 50 |
| P-01350 | 26% | S19 | BR-03 | no change | 34 |
| P-01430 | 39% | S05 | CR-01 | improved | 54 |
| P-01442 | 30% | S13 | CR-01 | improved | 61 |
| P-01654 | 28% | S08 | CR-01 | improved | 85 |